Gastric Fundal Mucosal Ablation for Weight Management in Patients Stopping Glucagon-like Peptide-1 Receptor Agonists
The purpose of this study is to assess the effect of gastric fundal mucosal ablation (GFMA) on weight trajectory following discontinuation of once-weekly semaglutide or tirzepatide in adults with obesity. In this study, GFMA will be performed on patients who have experienced \> 10% weight loss with GLP-1 therapy and who plan to discontinue use of GLP-1 medications for the duration of the study.
• Subjects aged 21-65
• Body mass Index (BMI) ≥30 kilograms per square meter (kg/m²), or ≤45 kg/m²
• Observed ≥ 10% TBWL with semaglutide or tirzepatide use for primary obesity therapy
• Subject did not experience \>50% weight recurrence since discontinuation of semaglutide or tirzepatide
• Maintained a stable dose of semaglutide or tirzepatide for a minimum of 12 weeks
• Have recently discontinued or are planning to discontinue semaglutide or tirzepatide (≤ 24 weeks from last dose to time of study procedure)
• No previous medical history of diabetes mellitus
• Willing and able to participate in the study procedures
• Understand and voluntarily sign the informed consent